Clozapine
- Generic Name
- Clozapine
- Brand Names
- Clozaril, Fazaclo, Versacloz
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19ClN4
- CAS Number
- 5786-21-0
- Unique Ingredient Identifier
- J60AR2IKIC
- Background
Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramida...
- Indication
Clozapine is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, Clozapine should be used only in patients who have failed to respond adequately to standard antipsychotic treatment.
...
- Associated Conditions
- Suicidal Behaviour, Treatment Resistant Schizophrenia, Advanced dopaminomimetic psychosis
- Associated Therapies
- -
F-18 Altanserin PET Study of Patients Receiving Clozapine
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT01398189
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of
Clozapine and Olanzapine Treatment of Aggression
- Conditions
- Interventions
- First Posted Date
- 2010-05-14
- Last Posted Date
- 2010-05-14
- Lead Sponsor
- Nathan Kline Institute for Psychiatric Research
- Target Recruit Count
- 110
- Registration Number
- NCT01123408
- Locations
- 🇺🇸
Nathan Kline Institute, Orangeburg, New York, United States
Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- University of Massachusetts, Worcester
- Target Recruit Count
- 66
- Registration Number
- NCT00981526
- Locations
- 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2021-02-21
- Target Recruit Count
- 147
- Registration Number
- NCT00649844
- Locations
Pfizer Investigational Site
First Episode Schizophrenia and Cannabis-Related Disorder Study
- Conditions
- Interventions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 14
- Registration Number
- NCT00573287
- Locations
- 🇺🇸
New Hampshire Hospital, Concord, New Hampshire, United States
🇺🇸Mental Health Center of Greater Manchester, Manchester, New Hampshire, United States
🇺🇸Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- Manhattan Psychiatric Center
- Target Recruit Count
- 20
- Registration Number
- NCT00501618
- Locations
- 🇺🇸
Manhattan Psychiatric Center, 125th Street, Out Patient Clinic, New York, New York, United States
🇺🇸Manhattan Psychiatric Center, Inpatient Unit, New York, New York, United States
Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
- Conditions
- Interventions
- First Posted Date
- 2007-07-10
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 31
- Registration Number
- NCT00498550
- Locations
- 🇺🇸
University Missouri, Kansas City, Missouri, United States
🇺🇸West LA VAHCS, Los Angeles, California, United States
🇺🇸University South Carolina, Columbia, South Carolina, United States
A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 43
- Registration Number
- NCT00250575
- Locations
- 🇯🇵
Novartis Investigational Site, Chiba, Japan
🇯🇵Novartis Investigative Site, Yamanashi, Japan
Clozapine IM and Aggression in Schizophrenic Patients
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-07-24
- Lead Sponsor
- Beersheva Mental Health Center
- Registration Number
- NCT00189995
- Locations
- 🇮🇱
Nes Ziona Medical Center, Nes Ziona, Israel
🇮🇱Beersheva Mental Health Center, Beersheva, Israel
Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- Harvard Medical School (HMS and HSDM)
- Target Recruit Count
- 66
- Registration Number
- NCT00169039
- Locations
- 🇺🇸
Commonwealth Research Center, Jamaica Plain, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.